The Catalyst

Most Recent Posts

01.21.14 | By Preet Bilinski

The next new addition to our “I am Research, Progress, Hope” series is a scientist from Pfizer who works in neuroscience – leading a multi-disciplinary team focusing on Alzheimer’s and other serious diseases of the brain including schizophrenia.

01.17.14 | By Kaelan Hollon

Like a complex puzzle, the research and development (R&D) process for new medicines requires many pieces to work concurrently to ensure success. From the patients who inspire us to the experts behind the research, every part is critical to a prosperous pipeline for patients suffering from some of the world’s most debilitating diseases.

01.17.14 | By Preet Bilinski

As we continue our discussion of STEM education this week, we’re providing a window into the daily lives of some of our member companies’ biopharmaceutical researchers and getting their advice for future STEM educated individuals in our “I am Research, Progress, Hope” series.

01.15.14 | By Kaelan Hollon

Just one week from today, PhRMA is joining with U.S. News and World Report for a forum on a very important topic: Science, math, engineering and technology education, better known as STEM education. Numerous studies have shown that the United States has a STEM problem. We are falling behind other countries, with our students ranking in the bottom half of OECD nations in both science and math literacy.

01.15.14 | By Stephanie Fischer

The rare disease community lost a champion last week when Sam Berns passed away at age 17 due to complications from progeria, an extremely rare genetic disease which causes accelerated aging. Last October, Sam shared his inspiring philosophy for a happy life in his talk at TEDxMidAtlantic.


Those who advocate more aggressive outreach to patients to talk about the potential benefits and importance of clinical research would certainly have felt vindicated during the roll out of "Research in Your Backyard: Pharmaceutical Clinical Trials in Iowa" yesterday in Des Moines.

01.10.14 | By Kaelan Hollon

This year promises to be a busy, productive one for PhRMA and our member companies, and we started the week off right by focusing on several key industry issues, including rare diseases, STEM education, and medical advances.

01.10.14 | By Josephine Martin

While 2013 was a great year, 2014 promises to be even better. As we look ahead, our focus on facilitating thoughtful discussions on some of the most important health care topics will continue.

01.10.14 | By Kaelan Hollon

Last week, the Administration gave a boost to NASA, vowing to keep the International Space Station in orbit until 2024, four years longer than its current approved tenure. With so many questions left unanswered and so much unchartered territory, space exploration is a lot like the search for treatments and cures.


Technology is rapidly changing how we conduct even the simplest of daily tasks, and with smartphones, tablets, and other mobile devices, being “connected” is no longer a function of sitting at a desk in front of a computer. We now carry some of the most powerful computers in the palm of our hands, and mobile platforms have opened the door to the creation of some incredibly innovative applications.

01.09.14 | By Dr. Bill Chin

Earlier this week, Scientific American published an excellent blog post by chemist Ashutosh Jogalekar with the cheeky title, “Why drugs are expensive: It’s the science, stupid.” In his well-informed commentary, Jogalekar describe


Looking for the latest data on retail prescription drug spending? We’ve got it here. Yesterday, CMS’ Office of the Actuary released its latest figures on national health care and prescription drug spending for 2012.


This is the third blog post in a series of responses to Luke Timmerman’s Xconomy article, “12 Things the Pharma Industry Can Do to Rebuild Real Public Trust,” in which he says the pharmaceutical industry isn’t doing enough to deliver “big health advances.”

01.07.14 | By Kaelan Hollon

A recent article in Information Week authored by Robert Atkinson, President of the Information Technology and Innovation Foundation, makes an interesting argument about why innovation-focused industries, such as the biopharmaceutical sector, should come together on issues of innovation in order to maintain U.S. competitiveness.


This is the second blog post in a series of responses to Luke Timmerman’s Xconomy article, “12 Things the Pharma Industry Can Do to Rebuild Real Public Trust,” in which he says the pharmaceutical industry isn’t doing enough to deliver “big health advances.